Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium + salmeterol versus fluticasone + salmeterol in COPD
2006-004086-33Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tiotropium, salmeterol and fluticasone propionate in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Thoracic gas volume at functional residual capacity and Endurance time. Started Jun 2007; status: completed.
02
Drugs
tiotropiumsalmeterolfluticasone propionate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-004086-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004086-33.